ROCKVILLE, Md. — Novavax, Inc. announced Nov. 2 that its seasonal flu vaccine candidate met key goals in a midstage clinical trial.
Three days earlier officials from clinical-stage biotechnology company appeared at the annual meeting of the Infectious Diseases Society of America.
Their presentation included data from a study of Novavax's trivalent seasonal influenza VLP vaccine that began in May among healthy adults 18 to 49 years old.
"We are pleased with the results of this study, which support continued development of novel VLP vaccines against influenza and moving forward with our head-to-head study in the elderly population this Fall," said Dr. Rahul Singhvi, president and CEO of Novavax.
"We believe that our VLP influenza vaccine has the potential to induce broad immunity against influenza including cross-reactivity against drifted strains which may emerge throughout an influenza season."
VLPs, or virus-like particles, mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology.
Novavax says its VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.